Almirall and Absci partner to develop AI-designed therapeutics for dermatological diseases

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, and Absci Corporation, a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.

source https://www.news-medical.net/news/20231120/Almirall-and-Absci-partner-to-develop-AI-designed-therapeutics-for-dermatological-diseases.aspx

Comments

Post a Comment

Popular posts from this blog

High levels of memory killer cells correlate with better survival in melanoma patients

Our skin contains specialized long-lived killer cells that protect against intruders. Researchers at Karolinska Institutet in Sweden and the University of Copenhagen in Denmark have now identified how these cells are formed, and shown that high levels of memory killer cells in cancer tissue correlate with a better survival rate in people with melanoma. source https://www.news-medical.net/news/20230602/High-levels-of-memory-killer-cells-correlate-with-better-survival-in-melanoma-patients.aspx
Read more

Sebum RNA could provide reliable biomarkers for detecting early-onset atopic dermatitis

Eczema is an inflammatory skin condition that often affects infants as young as one to two months. Among the various types of eczema seen in infants, early-onset atopic dermatitis (AD), characterized by psychological stress and sleep disorders, is particularly concerning. source https://www.news-medical.net/news/20230608/Sebum-RNA-could-provide-reliable-biomarkers-for-detecting-early-onset-atopic-dermatitis.aspx
Read more